Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Abrams

Showing results (331-340 of 367) with videos related to

Pageof 37
Sort By:
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Enzyme Regulation|March 27, 2007
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistanceJames A McCubrey, Linda S Steelman, Richard A Franklin, et al.
Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Advances in Biological Regulation|October 10, 2017
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticalsJames A McCubrey, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Advances in Enzyme Regulation|July 21, 2006
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Advances in Biological Regulation|July 8, 2018
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticalsStephen L Abrams, Kvin Lertpiriyapong, Li V Yang, et al.
Pageof 37

Showing results (331-340 of 367) with videos related to

Sort By:
Pageof 37
Advances in Biological Regulation|June 5, 2018
Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell linesWilliam H Chappell, Saverio Candido, Stephen L Abrams, et al.
Advances in Enzyme Regulation|March 27, 2007
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistanceJames A McCubrey, Linda S Steelman, Richard A Franklin, et al.
Expert Opinion on Emerging Drugs|September 1, 2009
Emerging Raf inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Expert Opinion on Emerging Drugs|February 16, 2010
Emerging MEK inhibitorsJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Advances in Biological Regulation|October 10, 2017
Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticalsJames A McCubrey, Stephen L Abrams, Kvin Lertpiriyapong, et al.
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Advances in Enzyme Regulation|July 21, 2006
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, Steven L Abrams, et al.
Advances in Biological Regulation|July 8, 2018
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticalsStephen L Abrams, Kvin Lertpiriyapong, Li V Yang, et al.
Pageof 37